title: Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products.
abstract: Elucidating the sites and mechanisms of sRAGE action in the healthy state is vital to better understand the biological importance of the receptor for advanced glycation end products (RAGE). Previous studies in animal models of disease have demonstrated that exogenous sRAGE has an anti-inflammatory effect, which has been reasoned to arise from sequestration of pro-inflammatory ligands away from membrane-bound RAGE isoforms. We show here that sRAGE exhibits in vitro binding with high affinity and reversibly to extracellular matrix components collagen I, collagen IV, and laminin. Soluble RAGE administered intratracheally, intravenously, or intraperitoneally, does not distribute in a specific fashion to any healthy mouse tissue, suggesting against the existence of accessible sRAGE sinks and receptors in the healthy mouse. Intratracheal administration is the only effective means of delivering exogenous sRAGE to the lung, the organ in which RAGE is most highly expressed; clearance of sRAGE from lung does not differ appreciably from that of albumin.
authors.affiliation: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Pavle S
authors.initials: PS
authors.lastname: Milutinovic
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
authors.forename: Judson M
authors.initials: JM
authors.lastname: Englert
authors.affiliation: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Lauren T
authors.initials: LT
authors.lastname: Crum
authors.affiliation: Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Neale S
authors.initials: NS
authors.lastname: Mason
authors.affiliation: Center for Insoluble Protein Structures, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
authors.forename: Lasse
authors.initials: L
authors.lastname: Ramsgaard
authors.affiliation: Center for Insoluble Protein Structures, Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Enghild
authors.affiliation: Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Sparvero
authors.affiliation: Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Lotze
authors.affiliation: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Tim D
authors.initials: TD
authors.lastname: Oury
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001682:Biological Availability; D024042:Collagen Type I / Q000378:metabolism*; D024141:Collagen Type IV / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007700:Kinetics; D007797:Laminin / Q000378:metabolism*; D008168:Lung / Q000737:chemistry / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011485:Protein Binding; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000008:administration & dosage / Q000302:isolation & purification / Q000378:metabolism*; D012995:Solubility
chemical_list: D024042:Collagen Type I; D024141:Collagen Type IV; D005353:Fibronectins; D007797:Laminin; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic